Nominate: Xconomy Awards →
May 13, 2020 · Boston
June 11, 2020 · New York
June 25, 2020 · San Francisco
December 5th, 2007
GlaxoSmithKline has written Lexington, MA-based Synta Pharmaceuticals (NASDAQ: SNTA) a check for $80 million. The payment is the first installment under a cancer-drug development agreement that could ultimately be worth $1.1 billion for the Lexington firm.
Rebecca is Xconomy's co-founder. Follow @
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
© 2007-2020, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.